Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KARL SITZ

Allopathic & Osteopathic Physicians Internal Medicine Allergy & Immunology

NPI
1518959691
CMS profile
23540
Location
LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$865.65

55 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $865.65 55

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KARL SITZ

NPI 1518959691 · CMS profile ID 23540

Allopathic & Osteopathic Physicians / Internal Medicine / Allergy & Immunology

LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518959691?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KARL SITZ, NPI 1518959691, CMS profile ID 23540. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518959691?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). KARL SITZ, NPI 1518959691, CMS profile ID 23540. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518959691?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
KARL SITZ, NPI 1518959691, CMS profile ID 23540, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1518959691?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

55 matching records · $865.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 55 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–55 of 55.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $11.1703/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801741007 CMS
Teva Pharmaceuticals USA, Inc. $13.2702/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839460219 CMS
GlaxoSmithKline, LLC. $10.5501/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803208151 CMS
GlaxoSmithKline, LLC. $11.5101/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803139581 CMS
GlaxoSmithKline, LLC. $14.5001/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802408653 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,479.56 52
PY2020 $435.59 37
PY2021 $865.65 55
PY2022 $812.74 47
PY2023 $6,968.42 67
PY2024 $4,115.96 14
PY2025 $1,714.84 32

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $328,329.31 75
PY2024 Recipient $1,709.87 9
PY2024 Principal investigator $407,521.39 105
PY2023 Recipient $963.28 2
PY2023 Principal investigator $153,156.23 24
PY2022 Principal investigator $159,543.28 38
PY2021 Principal investigator $391,514.53 45
PY2020 Principal investigator $154,250.42 16
PY2019 Principal investigator $251,142.54 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

75 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $1,640.65 12/19/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192108797
Principal investigator 1 CSL Behring $621.00 12/15/2025 Non-covered Recipient Entity
Acuro Research Inc
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252670100
Principal investigator 1 GlaxoSmithKline, LLC. $431.25 12/11/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192108761
Principal investigator 1 GlaxoSmithKline, LLC. $5,339.95 11/25/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192108815
Principal investigator 1 PFIZER INC. $518.65 11/25/2025 Non-covered Recipient Entity
ACURO RESEARCH INC
A PHASE 2B RANDOMIZED DOUBLEBLIND 12WEEK PLACEBOCONTROLLED STUDY WITH A 12WEEK DOUBLEBLIND EXTENSION PERIOD TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB PF06651600 IN ADULT PARTICIPANTS WITH CHRONIC SPONTANEOUS URTICARIA No dispute reported 06/30/2026 1228805775
Principal investigator 1 PFIZER INC. $1,687.33 11/25/2025 Non-covered Recipient Entity
ACURO RESEARCH INC
A PHASE 2B RANDOMIZED DOUBLEBLIND 12WEEK PLACEBOCONTROLLED STUDY WITH A 12WEEK DOUBLEBLIND EXTENSION PERIOD TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB PF06651600 IN ADULT PARTICIPANTS WITH CHRONIC SPONTANEOUS URTICARIA No dispute reported 06/30/2026 1228805780
Principal investigator 1 GlaxoSmithKline, LLC. $16,853.00 11/14/2025 Non-covered Recipient Entity
ACURO RESEARCH
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192108825
Principal investigator 1 GlaxoSmithKline, LLC. $6,912.50 10/23/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192108832
Principal investigator 1 CSL Behring $1,974.00 10/22/2025 Non-covered Recipient Entity
Acuro Research Inc
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252670096
Principal investigator 1 GlaxoSmithKline, LLC. $2,111.85 10/17/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192108803
Principal investigator 1 GlaxoSmithKline, LLC. $2,165.00 10/14/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192108773
Principal investigator 1 Novartis Pharmaceuticals Corporation $146.78 10/08/2025 Non-covered Recipient Entity
ACURO RESEARCH INC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190313145
Principal investigator 1 GlaxoSmithKline, LLC. $6,024.90 10/02/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192108779
Principal investigator 1 GlaxoSmithKline, LLC. $4,558.10 09/03/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165466
Principal investigator 1 GlaxoSmithKline, LLC. $3,282.50 08/27/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192108755
Principal investigator 1 GlaxoSmithKline, LLC. $5,234.50 08/04/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192108790
Principal investigator 1 Incyte Corporation $7.63 08/04/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547888
Principal investigator 1 Incyte Corporation $3.92 08/04/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547895
Principal investigator 1 Incyte Corporation $57.85 08/04/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547902
Principal investigator 1 Incyte Corporation $11.45 08/04/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547907
Principal investigator 1 Incyte Corporation $16.18 08/04/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547913
Principal investigator 1 Incyte Corporation $24.68 08/04/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547920
Principal investigator 1 Incyte Corporation $7.63 08/04/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547928
Principal investigator 1 Incyte Corporation $7.63 08/04/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547933
Principal investigator 1 Incyte Corporation $7.63 08/04/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547940
Principal investigator 1 GlaxoSmithKline, LLC. $25,164.70 07/23/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165470
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,054.00 07/15/2025 Non-covered Recipient Entity
ACURO RESEARCH INC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190313147
Principal investigator 1 CSL Behring $117.78 06/26/2025 Non-covered Recipient Entity
Acuro Research Inc
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252670092
Principal investigator 1 GlaxoSmithKline, LLC. $5,006.50 06/20/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192163905
Principal investigator 1 GlaxoSmithKline, LLC. $5,991.65 05/21/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192163902
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,200.00 05/16/2025 Non-covered Recipient Entity
ACURO RESEARCH INC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244051789
Principal investigator 1 Incyte Corporation $1,404.00 05/12/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547757
Principal investigator 1 GlaxoSmithKline, LLC. $18,054.75 04/23/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192163910
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $179.90 04/22/2025 Non-covered Recipient Entity
ACURO RESEARCH INC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244051875
Principal investigator 1 GlaxoSmithKline, LLC. $8,722.50 04/17/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192108809
Principal investigator 1 Incyte Corporation $1,404.00 04/14/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547761
Principal investigator 1 Incyte Corporation $6.86 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547750
Principal investigator 1 Incyte Corporation $16.32 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547767
Principal investigator 1 Incyte Corporation $57.81 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547773
Principal investigator 1 Incyte Corporation $5.88 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547778
Principal investigator 1 Incyte Corporation $173.55 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547784
Principal investigator 1 Incyte Corporation $74.34 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547796
Principal investigator 1 Incyte Corporation $22.90 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547803
Principal investigator 1 Incyte Corporation $173.55 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547808
Principal investigator 1 Incyte Corporation $11.45 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547814
Principal investigator 1 Incyte Corporation $22.89 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547821
Principal investigator 1 Incyte Corporation $22.89 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547826
Principal investigator 1 Incyte Corporation $22.89 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547832
Principal investigator 1 Incyte Corporation $22.89 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547838
Principal investigator 1 Incyte Corporation $22.89 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547849
Principal investigator 1 Incyte Corporation $22.89 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547855
Principal investigator 1 Incyte Corporation $22.89 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547860
Principal investigator 1 Incyte Corporation $22.89 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547865
Principal investigator 1 Incyte Corporation $20.16 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547869
Principal investigator 1 Incyte Corporation $57.81 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547875
Principal investigator 1 Incyte Corporation $74.34 04/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547882
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,007.92 03/25/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY AND ASTHMA CLINIC, PA
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod No dispute reported 06/30/2026 1185554052
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,682.90 03/19/2025 Non-covered Recipient Entity
ACURO RESEARCH, LNC
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185554050
Principal investigator 1 GlaxoSmithKline, LLC. $52,993.85 03/14/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192108785
Principal investigator 1 Incyte Corporation $983.40 03/14/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547725
Principal investigator 1 Incyte Corporation $1,803.00 03/14/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547729
Principal investigator 1 Incyte Corporation $2,009.00 03/14/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547740
Principal investigator 1 Incyte Corporation $1,573.00 03/14/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547746
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,225.70 03/11/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA CLINIC PA
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190299883
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,794.00 02/27/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA CLINIC PA
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190299887
Principal investigator 1 GlaxoSmithKline, LLC. $4,251.25 02/06/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192108749
Principal investigator 1 GlaxoSmithKline, LLC. $8,315.00 02/06/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192108820
Principal investigator 1 GlaxoSmithKline, LLC. $1,697.50 02/06/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192165475
Principal investigator 1 GlaxoSmithKline, LLC. $1,210.00 01/30/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192108768
Principal investigator 1 GlaxoSmithKline, LLC. $2,420.00 01/30/2025 Non-covered Recipient Entity
ACURO RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192163897
Principal investigator 1 CSL Behring $115.80 01/14/2025 Non-covered Recipient Entity
Acuro Research Inc
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252670090
Principal investigator 1 Incyte Corporation $73.92 01/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547719
Principal investigator 1 Incyte Corporation $272.58 01/02/2025 Non-covered Recipient Entity
LITTLE ROCK ALLERGY ASTHMA, PA CLINICAL RESEARCH CENTER LRAAC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240547736
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,645.19 01/01/2025 Non-covered Recipient Entity
ACURO RESEARCH
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190306723
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,430.87 01/01/2025 Non-covered Recipient Entity
ACURO RESEARCH
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190306725